Quantitation of cystic fibrosis triple combination therapy, elexacaftor/tezacaftor/ivacaftor, in human plasma and cellular lysate

Author:

Ryan Kevin J.,Guimbellot Jennifer S.,Dowell Alexander E.,Reed-Walker Kedria D.,Kerstner-Wood Corenna D.,Anderson Justin D.,Liu Zhongyu,Acosta Edward P.

Funder

National Center for Advancing Translational Sciences

National Heart Lung and Blood Institute

National Institute of Diabetes and Digestive and Kidney Diseases

Cystic Fibrosis Foundation

Publisher

Elsevier BV

Subject

Cell Biology,Clinical Biochemistry,Biochemistry,General Medicine,Analytical Chemistry

Reference34 articles.

1. Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy;Lubamba;Clin. Biochem,2012

2. B.W. Ramsey, J. Davies, N.G. McElvaney, E. Tullis, S.C. Bell, P. Drevinek, M. Griese, E.F. McKone, C.E. Wainwright, M.W. Konstan, R. Moss, F. Ratjen, I. Sermet-Gaudelus, S.M. Rowe, Q. Dong, S. Rodriguez, K. Yen, C. Ordonez, J.S. Elborn, V.X.S. Group, A CFTR potentiator in patients with cystic fibrosis and the G551D mutation, N Engl J Med, 365 (2011) 1663-1672.

3. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR;Wainwright;New Engl. J. Med.,2015

4. H.G.M. Heijerman, E.F. McKone, D.G. Downey, E. Van Braeckel, S.M. Rowe, E. Tullis, M.A. Mall, J.J. Welter, B.W. Ramsey, C.M. McKee, G. Marigowda, S.M. Moskowitz, D. Waltz, P.R. Sosnay, C. Simard, N. Ahluwalia, F. Xuan, Y. Zhang, J.L. Taylor-Cousar, K.S. McCoy, V.X.T. Group, Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial, Lancet, DOI https://doi.org/10.1016/S0140-6736(19)32597-8(2019).

5. P.G. Middleton, M.A. Mall, P. Drevinek, L.C. Lands, E.F. McKone, D. Polineni, B.W. Ramsey, J.L. Taylor-Cousar, E. Tullis, F. Vermeulen, G. Marigowda, C.M. McKee, S.M. Moskowitz, N. Nair, J. Savage, C. Simard, S. Tian, D. Waltz, F. Xuan, S.M. Rowe, R. Jain, V.X.S. Group, Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele, N Engl J Med, 381 (2019) 1809-1819.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3